Clinical Trials Browser

Recruiting × INDUSTRY × Alemtuzumab × Clear all

NCT04150497 2025-09-09

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Phase 1/2 Recruiting

Burkitt Lymphoma, Recurrence

NCT05607420 2025-08-24

NatHaLi-01

Phase 1/2 Recruiting

Recurrence, Lymphoma, B-Cell